|

Anifrolumab Clinical Trials

9 actively recruiting trials across 5 locations

▲ +1 trial since May 2026

Also known as: (MEDI-546), Saphnelo

Pipeline

Phase 2: 1Phase 3: 2Phase 4: 1

Top Sponsors

  • AstraZeneca8
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)1

Indications

  • Lupus9
  • Systemic Lupus Erythematosus7
  • Lupus Erythematosus, Systemic2
  • Premature Atherosclerosis1
  • Cardiovascular Disease1

Other4 trials

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Anifrolumab Malignancy and Serious Infections Study
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
The Anifrolumab PRIM Program

Anniston, Alabama1 trial

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Research Site

Phase 3

Phoenix, Arizona1 trial

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Research Site

Phase 3

Bethesda, Maryland1 trial

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

National Institutes of Health Clinical Center

Phase 2

Las Vegas, Nevada1 trial

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Research Site

Phase 4

Wilmington, North Carolina1 trial

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Research Site

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.